TY - JOUR
T1 - Radiotherapeutic bandage for the treatment of squamous cell carcinoma of the skin
AU - Koneru, Bhuvaneswari
AU - Shi, Yi
AU - Munaweera, Imalka
AU - Wight-Carter, Mary
AU - Kadara, Humam
AU - Yuan, Hong
AU - Di Pasqua, Anthony J.
AU - Balkus, Kenneth J.
N1 - Publisher Copyright:
© 2016 The Authors.
PY - 2016/6/1
Y1 - 2016/6/1
N2 - Introduction: Squamous cell carcinoma (SCC) is the second most common form of skin cancer in the United States. The efficacy of a pharmaceutically elegant radiotherapeutic bandage, previously described by us for application against SCC of the skin, was tested for the first time in vivo using a subcutaneous SCC mouse model and a therapeutically relevant radiation dose. Methods: Female athymic nude mice were injected with human Colo-16 SCC cells subcutaneously and after eight days (average tumor volume: 35 ± 8.6 mm3) received no treatment, or were exposed to non-radioactive or radioactive (92.5 ± 18.5 MBq) bandages for approximately 1 h (n = 10 per group). After treatment, tumors were measured over fifteen days, tumor volume ratios (TVRs) compared and histopathology performed. Results: Fifteen days after treatment, the TVR of the radioactive bandage treatment group was 3.3 ± 4.5, while TVRs of the non-radioactive bandage treatment and no treatment control groups were 33.2 ± 14.7 and 26.9 ± 12.6, respectively. At the time of necropsy, there was mild focal epidermal hyperplasia surrounding a small area of epidermal ulceration in the radioactive bandage group. No other examined tissue (i.e., muscle, liver, kidney, lung, spleen and heart) showed significant lesions. Conclusions: Our radiotherapeutic bandage exhibits promising efficacy against SCC of the skin in a mouse model. It can be individually tailored for easy application on tumor lesions of all shapes and sizes, and could complement or possibly replace surgery in the clinic.
AB - Introduction: Squamous cell carcinoma (SCC) is the second most common form of skin cancer in the United States. The efficacy of a pharmaceutically elegant radiotherapeutic bandage, previously described by us for application against SCC of the skin, was tested for the first time in vivo using a subcutaneous SCC mouse model and a therapeutically relevant radiation dose. Methods: Female athymic nude mice were injected with human Colo-16 SCC cells subcutaneously and after eight days (average tumor volume: 35 ± 8.6 mm3) received no treatment, or were exposed to non-radioactive or radioactive (92.5 ± 18.5 MBq) bandages for approximately 1 h (n = 10 per group). After treatment, tumors were measured over fifteen days, tumor volume ratios (TVRs) compared and histopathology performed. Results: Fifteen days after treatment, the TVR of the radioactive bandage treatment group was 3.3 ± 4.5, while TVRs of the non-radioactive bandage treatment and no treatment control groups were 33.2 ± 14.7 and 26.9 ± 12.6, respectively. At the time of necropsy, there was mild focal epidermal hyperplasia surrounding a small area of epidermal ulceration in the radioactive bandage group. No other examined tissue (i.e., muscle, liver, kidney, lung, spleen and heart) showed significant lesions. Conclusions: Our radiotherapeutic bandage exhibits promising efficacy against SCC of the skin in a mouse model. It can be individually tailored for easy application on tumor lesions of all shapes and sizes, and could complement or possibly replace surgery in the clinic.
KW - Bandages
KW - Carcinoma
KW - Nanostructures
KW - Radiotherapy
KW - Skin neoplasms
KW - Squamous cell
UR - http://www.scopus.com/inward/record.url?scp=84962853178&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84962853178&partnerID=8YFLogxK
U2 - 10.1016/j.nucmedbio.2016.02.010
DO - 10.1016/j.nucmedbio.2016.02.010
M3 - Article
C2 - 27260774
AN - SCOPUS:84962853178
SN - 0969-8051
VL - 43
SP - 333
EP - 338
JO - Nuclear Medicine and Biology
JF - Nuclear Medicine and Biology
IS - 6
ER -